PF-Atlas › Clinical Trials › NCT01614457

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CF Transmembrane Conductance Regulator Mutation

Ivacaftor · Phase 3

Registry ID
NCT01614457
Phase
Phase 3
Status
Completed
Drug / intervention
Ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2012-07
Enrollment
70
Locations
31

About this trial

The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.

View NCT01614457 on ClinicalTrials.gov →

Explore related

All Ivacaftor trialsAll IPF trials

Related trials

ivacaftor — NCT02445053Ivacaftor — NCT00953706Ivacaftor — NCT01705145Ivacaftor — NCT02934698Ivacaftor — NCT03068312ivacaftor — NCT02742519
Medical disclaimer. This page summarizes public trial data for NCT01614457 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.